Article
Leaders in focus: Exclusive interviews from ISPOR Europe 2025
At ISPOR Europe 2025 in Glasgow – the leading conference for Health Economics and Outcomes Research (HEOR) – we had the privilege of connecting with global healthcare leaders to explore today’s most pressing challenges and emerging opportunities in the field. This exclusive collection of expert interviews delves into critical topics, including the complexities of EU HTA, country-specific strategies, and the latest global policy changes shaping innovation and patient access. Discover insights from the forefront of healthcare innovation and policy to stay ahead.
Tackling market access and global policies: EU HTA Regulation in focus
Herbert Altman, Vice President, Market Access & Healthcare Consulting, Europe, at Cencora, and Alexander Natz, Secretary General at EUCOPE, explore the EU HTA Regulation’s role in reducing bureaucracy and improving patient access. At ISPOR Europe 2025, they discussed challenges like patient engagement, the influence of US Most Favored Nation policies, and the need for harmonized processes across Europe to keep the region competitive for pharmaceutical innovation.
Sweden’s perspective on EU HTA: Progress, challenges, and future goals
Niklas Hedberg, Chief Pharmacist of TLV and Co-Chair of the EU HTA Coordinating Group, shares Sweden’s role in the EU HTA Regulation, key milestones achieved, and the vision for 2028. In this interview, he highlights how collaboration, capacity-building, and stakeholder engagement can reduce disparities across member states and improve patient access to innovative therapies.
Expanding the role of health economics in France’s market access
Watch Isabelle Bourget, Pharmacist and Health Economist, and Professor at Institut Gustave Roussy, as she discusses the evolving role of health economic evaluations in France with Jean-Marc Pinguet, Market Access Lead, France and Benelux, at Cencora. Learn about current criteria for drug assessments, comparisons with other countries, and the potential for broader adoption of economic arguments in price negotiations. In this interview, Isabelle explores how these evaluations can support sustainability, innovation, and faster patient access in the French healthcare system.
Adopting an AI-first mindset: Perspectives on market access
Leanna Baker Williams, Market Access Manager at Cencora, and David Ringger, Director of Global Market Access and Pricing at Cencora, delve into how AI is revolutionizing market access workflows in this insightful interview. Drawing from the session "Integrating AI into market access workflows" at ISPOR Europe 2025 moderated by David Ringger, they share key insights on AI’s transformative role in enhancing systematic literature reviews (SLRs), improving efficiency, and overcoming regulatory challenges. Dive into this compelling conversation to learn how AI is shaping innovation and advancing patient access.
Keeping pace with change: Reflections on US policy shifts and their impact on access in Europe
Casper Paardekooper, Head of Pricing, Policy and Stakeholder Engagement, Europe at Cencora, speaks with Neil Grubert, independent global market access advisor, about how fast-moving US policy developments are influencing Europe’s market access landscape. In this video, they explore the uncertainty these changes are creating, potential ripple effects through international reference pricing, and why some companies are taking a more cautious approach to launch planning. The conversation also touches on Europe’s competitiveness ambitions and the need for balanced EU pharmaceutical legislation that supports both access and innovation.
Meaningful patient involvement: Strengthening HTA and access decisions with patient insights
Casper Paardekooper, Head of Pricing, Policy and Stakeholder Engagement, Europe at Cencora, speaks with Antonella Cardone, CEO of Cancer Patients Europe (CPE), about why patient insights are essential to stronger health technology assessment (HTA) and market access decisions. In this video, they discuss the value of lived experience, the benefits of earlier and more systematic involvement, and the capability building patient organisations need to participate effectively.
Advancing ATMP access in Italy and Europe
The ATMP Forum, launched in 2017, brings together the stakeholders shaping advanced therapy medicinal products (ATMPs) in Italy and beyond: patients, clinicians, researchers, national and regional institutions, scientific societies, health economists, industry, and AIFA.
Its goal is simple but urgent: remove barriers and accelerate sustainable, equitable patient access to advanced therapies — recognizing their complexity and the need to evolve assessment and implementation models.
At ISPOR Europe 2025, Herbert Altmann, Vice President, Market Access and Healthcare Consulting Europe at Cencora, sat down with Marianna Morani, Senior Manager, Market Access Italy, to talk about the ATMP Forum and the newly released 8th ATMP Report.
In this interview, Marianna and Herbert share key insights from the latest report, including the current European and Italian ATMP landscape (21 active EU marketing authorizations; 15 therapies reimbursed in Italy) and a critical access challenge: an average seven-month gap between national price and reimbursement and the first regional purchase. They also highlight Cencora-led initiatives such as horizon scanning, a patient-focused ATMP Forum, a multi-regional network to support regional programming, and a sustainability hackathon generating practical solutions for the system. Email our team at info@atmpforum.com to connect and get access to the ATMP Report from the 2025 ATMP Forum event.
Additional insights
Article
Navigating global policy shifts: Insights from ISPOR Europe 2025
The global healthcare landscape is rapidly evolving, with Europe’s pharmaceutical industry facing pressures from U.S. policy changes and China’s growing pharmaceutical ecosystem. At ISPOR Europe 2025, our expert Casper Paardekooper, Head of Pricing, Policy and Stakeholder Engagement, had the honor of moderating the symposium, “Navigating Global Policy Shifts: Implications for Europe’s Pharmaceutical Pricing, Market Access, and HTA Landscape,” featuring a panel of esteemed experts. Together, we examined the impact of global policy changes on Europe’s healthcare systems, opportunities for adaptation, and the importance of collaboration to drive innovation.
Article
Harmonizing Health Technology Assessment: PICO consolidation under the EU HTA Regulation
The EU HTA regulation (EU HTAR) is reshaping global market access, bringing both opportunities and challenges for manufacturers. In this exclusive Corporate partner insights interview by ISPOR, Ruairi O'Donnell, Vice President of Market Access and Healthcare Consulting Europe at Cencora, joins Dr. Patti Peeples to explore how the industry can adapt to this new reality. Ruairi shares actionable strategies to navigate the complexities of EU HTA and PICO consolidation. From harmonizing clinical evidence across Europe to addressing unrealistic comparators and leveraging real-world evidence (RWE), this discussion provides a roadmap for success.
Cencora solution
EU Health Technology Assessment (HTA) consulting
As the European Union takes bold strides towards harmonizing and enhancing its healthcare landscape, the implementation of the Joint Clinical Assessment (JCA) stands as a pivotal moment. At Cencora, we help companies at all stages of the EU HTA journey, from early evidence to post-JCA implementation at the national level.
Connect with our team
Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.
